Found: 302
Select item for more details and to access through your institution.
Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE‐O trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 12, p. 6080, doi. 10.1111/dom.15957
- By:
- Publication type:
- Article
Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2012, v. 28, n. 3, p. 258, doi. 10.1002/dmrr.1305
- By:
- Publication type:
- Article
Abstract 171: Greater time spent in glycaemic control with oral semaglutide vs oral comparators.
- Published in:
- Indian Journal of Endocrinology & Metabolism, 2022, v. 26, p. 73, doi. 10.4103/2230-8210.363677
- By:
- Publication type:
- Article
Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
- Published in:
- 2000
- By:
- Publication type:
- journal article
Glycated Albumin Correlates With Time-in-Range Better Than HbA<sub>1c</sub> or Fructosamine.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2023, v. 108, n. 11, p. e1193, doi. 10.1210/clinem/dgad298
- By:
- Publication type:
- Article
Results of a Study Comparing Glycated Albumin to Other Glycemic Indices.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Management of prediabetes: setting the stage.
- Published in:
- 2007
- By:
- Publication type:
- Editorial
Blood Glucose and Diabetic Complications.
- Published in:
- Annals of Internal Medicine, 1986, v. 105, n. 2, p. 254, doi. 10.7326/0003-4819-105-2-254
- By:
- Publication type:
- Article
Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2011, v. 96, n. 6, p. 1695, doi. 10.1210/jc.2010-2822
- By:
- Publication type:
- Article
Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trial.
- Published in:
- Cardiovascular Diabetology, 2024, v. 23, n. 1, p. 1, doi. 10.1186/s12933-024-02432-7
- By:
- Publication type:
- Article
Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy.
- Published in:
- Cardiovascular Diabetology, 2024, v. 23, n. 1, p. 1, doi. 10.1186/s12933-024-02378-w
- By:
- Publication type:
- Article
Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial.
- Published in:
- Cardiovascular Diabetology, 2024, v. 23, n. 1, p. 1, doi. 10.1186/s12933-024-02135-z
- By:
- Publication type:
- Article
Correction to: Dose–response effects on HbA<sub>1c</sub> and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Dose–response effects on HbA<sub>1c</sub> and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
- Published in:
- Diabetologia, 2024, v. 67, n. 3, p. 470, doi. 10.1007/s00125-023-06053-9
- By:
- Publication type:
- Article
Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant‐level pooled analysis of three phase 3 LixiLan randomized controlled trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 11, p. 5046, doi. 10.1111/dom.15811
- By:
- Publication type:
- Article
Once‐weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant‐level meta‐analysis of the ONWARDS 1–5 trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 9, p. 3810, doi. 10.1111/dom.15726
- By:
- Publication type:
- Article
Once‐weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 8, p. 3020, doi. 10.1111/dom.15604
- By:
- Publication type:
- Article
Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR‐Pooled analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 7, p. 2578, doi. 10.1111/dom.15572
- By:
- Publication type:
- Article
Cardiovascular and renal outcomes with varying degrees of kidney disease in high‐risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE‐O trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 4, p. 1216, doi. 10.1111/dom.15417
- By:
- Publication type:
- Article
Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 3, p. 851, doi. 10.1111/dom.15377
- By:
- Publication type:
- Article
Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 2, p. 532, doi. 10.1111/dom.15339
- By:
- Publication type:
- Article
Impact on glycated haemoglobin and body weight changes after stopping tirzepatide for 4 weeks in the SURPASS‐1 monotherapy trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 1, p. 396, doi. 10.1111/dom.15325
- By:
- Publication type:
- Article
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 6, p. 1646, doi. 10.1111/dom.15019
- By:
- Publication type:
- Article
Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 6, p. 1453, doi. 10.1111/dom.14991
- By:
- Publication type:
- Article
Oral insulin (ORMD‐0801) in type 2 diabetes mellitus: A dose‐finding 12‐week randomized placebo‐controlled study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 943, doi. 10.1111/dom.14901
- By:
- Publication type:
- Article
Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 656, doi. 10.1111/dom.14907
- By:
- Publication type:
- Article
Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. 331, doi. 10.1111/dom.14871
- By:
- Publication type:
- Article
Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 12, p. 2391, doi. 10.1111/dom.14825
- By:
- Publication type:
- Article
Improved patient‐reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 12, p. 2364, doi. 10.1111/dom.14822
- By:
- Publication type:
- Article
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 8, p. 1553, doi. 10.1111/dom.14725
- By:
- Publication type:
- Article
Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 7, p. 1338, doi. 10.1111/dom.14710
- By:
- Publication type:
- Article
Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan‐O randomized trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 34, doi. 10.1111/dom.14543
- By:
- Publication type:
- Article
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2632, doi. 10.1111/dom.14513
- By:
- Publication type:
- Article
Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 7, p. 1588, doi. 10.1111/dom.14372
- By:
- Publication type:
- Article
Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial subgroup analysis by HbA1c and GLP‐1 RA use at screening
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1331, doi. 10.1111/dom.14345
- By:
- Publication type:
- Article
Titratable fixed‐ratio combination of basal insulin plus a glucagon‐like peptide‐1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 7, p. 1445, doi. 10.1111/dom.14365
- By:
- Publication type:
- Article
Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin‐treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1221, doi. 10.1111/dom.14354
- By:
- Publication type:
- Article
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 569, doi. 10.1111/dom.14254
- By:
- Publication type:
- Article
Design and baseline characteristics of the AMPLITUDE‐O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon‐like peptide‐1 receptor agonist.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 318, doi. 10.1111/dom.14223
- By:
- Publication type:
- Article
Real‐world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon‐like peptide‐1 receptor agonists.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2295, doi. 10.1111/dom.14154
- By:
- Publication type:
- Article
Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the LixiLan‐G trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 9, p. 1567, doi. 10.1111/dom.14068
- By:
- Publication type:
- Article
Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 8, p. 1243, doi. 10.1111/dom.14042
- By:
- Publication type:
- Article
Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 8, p. 1369, doi. 10.1111/dom.14043
- By:
- Publication type:
- Article
Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo‐controlled CARMELINA® trial
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1062, doi. 10.1111/dom.13995
- By:
- Publication type:
- Article
Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 427, doi. 10.1111/dom.13945
- By:
- Publication type:
- Article
Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 346, doi. 10.1111/dom.13901
- By:
- Publication type:
- Article
Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 303, doi. 10.1111/dom.13896
- By:
- Publication type:
- Article
Triple therapy with low‐dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 9, p. 2152, doi. 10.1111/dom.13795
- By:
- Publication type:
- Article
FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 5, p. 1073, doi. 10.1111/dom.13645
- By:
- Publication type:
- Article
Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 4, p. 883, doi. 10.1111/dom.13594
- By:
- Publication type:
- Article